Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00319
2012-04-24
Prospective
N/A
CUHK Neurology Research Fund
N/A
N/A
Miss Joan Khoo
Room 124010, 10/F, Clinical Sciences Building, Prince of Wales Hospital, Shatin, NT, Hong Kong
2632 3856
crjoankhoo@gmail.com
Department of Medicine & Therapeutics
Professor Vincent Mok
Room 114028, 9/F, Clinical Sciences Building, Prince of Wales Hospital, Shatin, NT, Hong Kong
2632 2195
vctmok@cuhk.edu.hk
Department of Medicine & Therapeutics
Statins and White Matter Lesion Progression: A Randomised, Open-Label, Parellel Group Study
Statins and White Matter Lesion Progression: A Randomised, Open-Label, Parellel Group Study
N/A
Hong Kong
Yes
2012-03-06
The effects of statins upon White Matter Lesion progression in dementia free stroke survivors who have confluent White matter leision
Drug
Simvastatin : 40mg daily
Atorvastatin : 40mg daily / 60 mg daily / 80 mg daily
2 years
Simvastatin 10 mg
(1)Ischemic stroke patients aged 40-90
(2) MRI brain showing early confluent to confluent White Matter Lesion (Fazekas grading of 2 to 3)
(3) LDL cholesterol level of >=3 mmol/L
(4) Sufficient Chinese competency for cognitive testing
(5) Informed written consent given
(1)Stroke within 3 months of screening visit
(2)History of hemorrhagic stroke
(3)Dementia as defined by diagnostic and statistical manual, 4th edition (DSM-IV)
(4)History of ischemic heart disease
(5)Severe stroke (Modified Rankin scale (mRS) of > = 5 or aphasia that hinders cognitive assessment
(6)Significant medical co-morbidities associated with limited life expectancy
(7)Change of lipid-altering drugs within 3 months of screening visit
(8)Other contraindications to statins e.g. Alanine transferase (ALT of > 20% of upper limit of normal,
(9)elevated creatinine phosphokinae(CPK) level>180 µmol/L or allergy to statins
40
90
Both Male and Female
Interventional
Randomized
Dose comparison
Open label
Parallel
2012-06-01
100
Unknown
Change of MRI White Matter lesion Volume
Time of measurement: Baseline, 1 year and 2 year MRI
(1)Change in other brain measures
- lacunar infarcts
- Microbleeds
- brain volume
- diffusion tensor imaging
- breath holding index
- pulsatility index
(2)Change in clinical measures
- MoCA
- Executive and memory tests
- Instrumental activities of daily living [IADL]
- Behavior
- Gait
Time of Measurement - Baseline, 1 year and 2 year visits
2015-08-11
ChiCTR-TRC-12002138
2012-05-01
Yes
N/A
|
|
|
|
|
---|---|---|---|---|
No documents yet. |